Trials / Completed
CompletedNCT02540954
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 336 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 51 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
Detailed description
330 Patients who have completed at least one year of treatment with aflibercept will be randomized to two different aflibercept regimens and followed for 76 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | A dose of 2 mg aflibercept injected intravitreally |
Timeline
- Start date
- 2015-09-29
- Primary completion
- 2019-12-24
- Completion
- 2020-06-04
- First posted
- 2015-09-04
- Last updated
- 2021-06-11
- Results posted
- 2021-04-08
Locations
71 sites across 14 countries: Austria, Canada, Czechia, France, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Slovakia, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02540954. Inclusion in this directory is not an endorsement.